Krystal Biotech Inc (KRYS)
159.99
-1.61
(-1.00%)
USD |
NASDAQ |
May 31, 16:00
160.02
+0.02
(+0.02%)
After-Hours: 20:00
Krystal Biotech Enterprise Value: 4.031B for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 4.031B |
| May 30, 2024 | 4.077B |
| May 29, 2024 | 3.927B |
| May 28, 2024 | 4.003B |
| May 24, 2024 | 4.112B |
| May 23, 2024 | 4.134B |
| May 22, 2024 | 4.295B |
| May 21, 2024 | 4.226B |
| May 20, 2024 | 4.158B |
| May 17, 2024 | 4.148B |
| May 16, 2024 | 4.139B |
| May 15, 2024 | 4.122B |
| May 14, 2024 | 4.016B |
| May 13, 2024 | 3.883B |
| May 10, 2024 | 3.881B |
| May 09, 2024 | 3.995B |
| May 08, 2024 | 3.965B |
| May 07, 2024 | 4.081B |
| May 06, 2024 | 3.944B |
| May 03, 2024 | 4.062B |
| May 02, 2024 | 4.038B |
| May 01, 2024 | 4.022B |
| April 30, 2024 | 3.835B |
| April 29, 2024 | 3.974B |
| April 26, 2024 | 3.937B |
| Date | Value |
|---|---|
| April 25, 2024 | 3.903B |
| April 24, 2024 | 3.999B |
| April 23, 2024 | 4.084B |
| April 22, 2024 | 3.948B |
| April 19, 2024 | 3.984B |
| April 18, 2024 | 4.139B |
| April 17, 2024 | 4.301B |
| April 16, 2024 | 4.314B |
| April 15, 2024 | 4.304B |
| April 12, 2024 | 4.415B |
| April 11, 2024 | 4.595B |
| April 10, 2024 | 4.474B |
| April 09, 2024 | 4.590B |
| April 08, 2024 | 4.609B |
| April 05, 2024 | 4.597B |
| April 04, 2024 | 4.553B |
| April 03, 2024 | 4.536B |
| April 02, 2024 | 4.509B |
| April 01, 2024 | 4.485B |
| March 31, 2024 | 4.538B |
| March 28, 2024 | 4.541B |
| March 27, 2024 | 4.521B |
| March 26, 2024 | 4.434B |
| March 25, 2024 | 4.300B |
| March 22, 2024 | 4.201B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
286.24M
Minimum
Jun 14 2019
4.609B
Maximum
Apr 08 2024
1.470B
Average
1.170B
Median
Enterprise Value Benchmarks
| Axsome Therapeutics Inc | 3.337B |
| Madrigal Pharmaceuticals Inc | 4.093B |
| Alnylam Pharmaceuticals Inc | 17.43B |
| Catalyst Pharmaceuticals Inc | 1.600B |
| Cytokinetics Inc | 5.086B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 0.932M |
| Revenue (Quarterly) | 45.25M |
| Total Expenses (Quarterly) | 39.43M |
| EPS Diluted (Quarterly) | 0.03 |
| Gross Profit Margin (Quarterly) | 94.65% |
| Profit Margin (Quarterly) | 2.06% |
| Earnings Yield | 1.18% |